RNA-guided engineered nucleases derived from a prokaryotic adaptive immune system known as CRISPR-Cas represent a promising platform for gene deletion and editing. As a therapeutic approach, direct delivery of Cas9 protein and guide RNA could circumvent the safety problems associated with plasmid delivery and therefore represents an attractive tool for genome engineering. Gene deletion or editing in adipose tissue to enhance its energy expenditure, fat oxidation and secretion of bioactive factors through a "browning" process presents a potential therapeutic strategy to alleviate metabolic disease. Here, we developed novel CRISPR delivery particles, denoted CriPs, composed of nano-size complexes of Cas9 protein and single guide (sg)RNA, coated with an amphipathic peptide called Endo-Porter that mediates entry into cells.
INTRODUCTION
Gene editing based on the clustered regularly interspaced short palindromic repeats (CRISPR) -associated protein 9 (Cas9) system presents significant therapeutic potential for treating a wide range of diseases (1) (2) (3) (4) . The CRISPR-Cas9 system, containing the RNA-guided nuclease (Cas9 protein) and a single guide RNA (sgRNA), recognizes a protospacer-adjacent motif (PAM) and generates double-stranded DNA breaks (DSBs) at 3 base pairs upstream of a PAM site (5) . DSBs are repaired by non-homologous end joining (NHEJ) to generate permanent gene deletion by inducing random insertions and deletions (indels) and by homology directed repair (HDR) to correct gene mutations with the use of a guide template DNA (5) . A key challenge for CRISPRCas9 based therapeutics is the efficient, safe delivery of genome editing macromolecules to achieve eventual translation to clinical efficacy and safety (6) (7) (8) (9) . Viral vectors including adenoassociated virus (AAV) have shown efficient in vivo delivery and expression of CRISPRCas9 (10) (11) (12) (13) . However, it is difficult to fit coding sequences for Streptococcus pyogenes Cas9 (SpCas9) plus sgRNAs into AAV vectors due to the restricted packaging capacity of AAVs (14) .
AAV-based Cas9 delivery also tends to cause significant off-target genome damage due to the sustained expression of Cas9 (15, 16) . In addition, the immune response to AAV capsids and the immunogenicity of the long-term existing bacterial Cas9 protein can limit their applications in human (11) . Physical delivery approaches of CRISPR-Cas9, such as electroporation (17) (18) (19) , micro-injection (20) and hydrodynamic injection (21, 22) , have also been successfully used, but with concerns such as cell viability, toxicity and difficulty to apply in vivo.
The limitations associated with both viral delivery and physical delivery can be addressed using non-viral delivery systems such as lipid nanoparticles (23) (24) (25) (26) (27) , DNA nanoclew (28) , gold nanoparticles (29, 30) , as well as chemically conjugating Cas9 protein with polymers (31) and cell penetrating peptides (32) . Furthermore, direct delivery of Cas9-sgRNA ribonucleoprotein (RNP) is being considered as a promising therapeutic strategy. Cas9-sgRNA RNP delivery could circumvent the safety problems associated with plasmid delivery such as uncontrolled integration of DNA segments into the host genome and unwanted immune response to plasmids encoding Cas9 protein and sgRNA (6) . Therefore, non-viral delivery of Cas9-sgRNA RNP represents an attractive tool for genome engineering. Cas9-sgRNA RNP delivered by non-viral delivery systems has been tested in cell culture (30, 33) , primary cells (15, 19) and for local delivery such as inner ear injection (4, 23) , skin injection (18) , intra-tumor injection (28) , intramuscular injection (29) and intracranial injection (34) . However, to the best of our knowledge, Cas9-sgRNA RNP has not yet been tested systemically in vivo using a fully non-viral delivery system. Application of CRISPR in therapies for type 2 diabetes would be attractive since this malady and its complications afflicts around 30 million adults in the United States and is a leading cause of death (35) . White adipose tissue (WAT) stores triglycerides and expands greatly during the onset of obesity, which can prompt insulin resistance, failure of insulin secretion and the development of type 2 diabetes(36). Unlike WAT, brown adipose tissue (BAT) is composed of brown adipocytes that display high capacity for fat oxidation and a high number of mitochondria containing uncoupling protein 1 (UCP1) for nonshivering thermogenesis that plays a beneficial role in metabolism (37) . BAT can also secrete beneficial factors to increase glucose uptake and fatty acid oxidation in other tissues (38, 39) . Recent data indicate that increased BAT can favorably control whole-body glucose homeostasis and is associated with lean, insulin sensitive phenotypes (40) (41) (42) . White adipocytes can be converted to brown or "beige" adipocytes by silencing molecular targets that suppress energy expenditure, fatty acid oxidation and insulin signaling, such as the nuclear co-repressor Nrip1 gene (43, 44) (also denoted as RIP140). Nrip1 silencing by RNAi in white adipocytes leads to adipocyte "browning" and enhances fatty acid oxidation, mitochondrial respiration and insulin mediated glucose uptake (43) . Nrip1 null mice present lean phenotypes with improved insulin sensitivity and glucose tolerance (45) , suggesting that Nrip1 is a powerful molecular target for alleviating type 2 diabetes. However, NRIP1 is not easily "druggable" by small molecules. Side effects may occur if inhibition of Nrip1 is not restricted to adipocytes and muscle (46) . Thus, an effective therapeutic strategy for targeting Nrip1 requires its gene deletion specifically in adipocytes or skeletal muscle or both, rather than in other tissues or through whole-body targeting.
Here, we developed a novel CRISPR delivery system, denoted CRISPR delivery particles (CriPs), composed of nano-size complexes of the CRISPR components Cas9 protein and sgRNA targeting a gene of interest, complexed with an Endo-Porter (EP) peptide that mediates entry into cells. EP is an amphipathic peptide composed of leucine and histidine residues, which we have previously used successfully for targeted siRNA delivery in cells (47) (48) (49) (50) . It is hypothesized that the weak-base histidine residues of EP facilitate the endosomal escape of the cargoes by the "proton-sponge effect" (51) . As proof of concept, efficient CRISPR-Cas9 mediated gene deletion of the green fluorescent protein (Gfp) gene was observed in multiple cell types isolated from GFP transgenic mice including primary macrophages and primary pre-adipocytes. GFP loss was achieved in about 50% of macrophages and primary pre-adipocytes as determined by flow cytometry analysis, in response to treatment with CriPs targeting Gfp. Indels in the Gfp genomic locus were confirmed by measurements using a T7 endonuclease I (T7E1) assay. Significant GFP loss was also observed in peritoneal exudate cells (PECs) isolated from GFP transgenic mice after 5 daily intraperitoneal (i.p.) injections with CriPs targeting Gfp as determined by flow cytometry and confirmed by nucleotide sequencing. To our knowledge, this is the first study suggesting that Cas9-sgRNA RNP can be systemically delivered in vivo by a simple non-viral system to achieve significant gene deletion efficiency. Furthermore, deletion of the Nrip1 gene in white adipocytes by CriPs converted them to a more "brown" adipocyte phenotype, with a remarkable increase of UCP1 expression and no detectable off-target effects as determined by T7E1 assay.
RESULTS

Design and Characterization of CriPs
The goal of the present study was to develop a simple delivery vehicle to effect specific gene deletion via the CRISPR-Cas9-based genome targeting mechanism. For therapeutic applications, we aimed to directly deliver Cas9 protein rather than plasmids that encode the protein to overcome such problems as uncontrolled integration of plasmid DNA into the host genome, unwanted immune responses and safety issues. Here, we report the preparation of CriPs that can deliver Cas9 protein bound to sgRNA to mediate gene deletion in vitro and in vivo (Fig. 1) .
Purified bacterial Cas9 protein that is carefully processed to remove endotoxin and other contaminants is used for loading of sgRNA. The sgRNA sequence is designed to target a selected gene at a site adjacent to a PAM sequence in the DNA of that target gene. The loaded Cas9-sgRNA complexes are then complexed with amphipathic EP peptide, which is designed to mediate the uptake of the Cas9-sgRNA complexes into live cells without toxicity or detectable damage. The inert CriPs contain only the three molecular components shown in Figure 1 (Cas9 protein, sgRNA and EP). As opposed to gene therapy approaches, no permanent viral vectors or genetic insertions of viral DNA are utilized. Cas9 protein that enters cells through transfection mechanisms lasts no longer than 24 hours within cells (52) . The EP peptide and the sgRNA are also rapidly degraded within cells. Thus, for ex vivo therapeutic approaches such as cell therapy and transplantation of ex vivo engineered tissue, Cas9 and other components in CriPs are not present in cells that are implanted. Additionally, unlike RNAi-based approaches, CriPs-mediated gene editing lasts for the lifespan of a cell, which allows for less frequent therapeutic administration and less chances of immune response or chronic toxicity.
CriPs with different ratios of EP to Cas9-sgRNA complexes were prepared and measured for their sizes and charges (Table 1) (Fig. 2B ).
To optimize the gene deletion efficiency of CriPs in GFP-J774A.1 cells, we first determined the relationship between CriP dose and response by changing the concentrations of the Cas9-Gfp sgRNA complexes. GFP loss was observed in about 50% of the GFP-J774A.1 cells treated within the range of 100 nM to 300 nM of the Cas9-Gfp sgRNA complexes (Fig. 2C) . We next tested the effect of the Cas9-sgRNA molar ratio on the gene deletion efficiency. A maximum loss of GFP in 53.3% of the GFP-J774A.1 cells was observed in response to CriPs loaded with a 1:1 molar ratio of Cas9 and Gfp sgRNA (Fig. 2D) . By assessing the effect of EP concentration on Gfp deletion efficiency, a maximum GFP loss in 53.4% of the GFP-J774A.1 cells was observed with 2 µM of EP (Fig. 2E) , which is the highest concentration of EP that was not associated with detectable cytotoxicity (Fig. S3) .
To confirm the loss of GFP in the GFP-J774A.1 cells was due to genome engineering by the CriPs targeting the Gfp gene, the frequency of indel mutations in the Gfp genomic locus was determined by T7E1 assay. The cells treated with CriPs targeting Gfp (Cas9-Gfp sgRNA -EP) showed 40.4% of indels in the Gfp genomic locus, while the cells treated with EP alone showed only background noise (Fig. 2F) . T7E1 assay usually underestimates the mutation frequencies due to the efficiency of the polymerase chain reaction (PCR) and the cleavage property of the T7 Endonuclease I(53). T7E1 recognizes and cleaves non-perfectly matched DNA at the first, second or third phosphodiester bond that is upstream of the mismatch. T7E1 cleaves heteroduplex DNA but does not recognize homozygous mutations, completely ignores single polymorphisms (SNPs) and also tends to miss small indels (53) .
Comparison of CriPs versus Lipofectamine® RNAiMAX in vitro
To compare the gene deletion efficiency by CriPs versus Cas9-sgRNA delivered by commercially available transfect agents, we treated the GFP-J774A.1 cells with either CriPs loaded with Gfp sgRNA or Cas9-Gfp sgRNA plus Lipofectamine® RNAiMAX. At two time points, 48 hours or 5 days post treatment of Cas9-Gfp sgRNA -RNAiMAX, a GFP shift or loss was observed as determined by flow cytometry in 29.4% and 29.8% of GFP-J774A.1 cells, respectively ( Fig. 2G and Fig. S2 ). Cas9-Gfp sgRNA delivered by Lipofectamine® RNAiMAX showed less Gfp gene deletion efficiency compared to CriPs which showed a GFP loss in over 50% of cells (Fig. 1B) . To optimize the gene deletion efficiency of Cas9-Gfp sgRNA delivered by Lipofectamine® RNAiMAX in GFP-J774A.1 cells, the concentrations of the Cas9-Gfp sgRNA complexes (Fig. S2B & S2D ) and the molar ratio of the Cas9-Gfp sgRNA complexes were optimized (Fig. S2E & S2F) . A maximum loss of GFP was observed in 20-30% of the GFP-J774A.1 cells treated with the range of 100 nM to 300 nM of the Cas9-Gfp sgRNA complexes at molar ratios of 1:1 to 1:5. These experiments suggest that Gfp gene deletion by Cas9-Gfp sgRNA delivered using Lipofectamine® RNAiMAX was not as efficient as the CriPs in GFP-J774A.1 cells (Fig. 1A-E and Fig. S1 ).
Gfp deletion in primary white pre-adipocytes from GFP mice
To investigate whether CriPs can efficiently delete genes in primary pre-adipocytes in vitro, showed only a background noise of 0.84% of the negative GFP pre-adipocytes (Fig. 3A) . To optimize the EP dose that causes the maximum gene deletion efficiency of Gfp by CriPs formulated in NEBuffer 3 in the primary GFP pre-adipocytes, the relationship between EP dose and response was determined. A maximum GFP loss was achieved in about 43.7% ± 3.0% of the GFP pre-adipocytes when the Cas9-Gfp sgRNA complexes (100 nM) were coated with 30 µM of the EP (Fig. 3B) . Interestingly, the loss of GFP was not complete after five days post transfection, as flow cytometry analysis showed a mixed population of cells that either displayed a complete loss of GFP, a shift in GFP loss, or no GFP loss. These variations can possibly be explained by the fact that the GFP transgenic mice likely have multiple Gfp transgenes inserted into their genome (54) .
When CriPs were formulated in PBS, a loss of the GFP signal in 35.1% of the GFP preadipocytes was observed when treated with CriPs targeting Gfp (Cas9-Gfp sgRNA -EP), while the control CriPs (Cas9-Control sgRNA -EP) showed a background of 1.05% loss (Fig. 3C ). The dose-response relationship of EP indicated a maximum GFP loss in about 35.8% ± 0.8% of the primary GFP pre-adipocytes treated with the CriPs loaded with the Cas9-Gfp sgRNA complexes (100 nM) coated with 15 µM of the EP (Fig. 3D) . Thus, the gene deletion efficiency is dependent on the formulations of the CriPs in different buffer systems coated with different doses of EP.
To confirm the loss of the GFP in the primary GFP pre-adipocytes was due to genome engineering by the CriPs targeting the Gfp gene, we performed T7E1 assay to determine the mutation frequency of indels in the Gfp genomic locus. Compared to the cells treated with control CriPs, cleaved products were observed in the cells treated with CriPs targeting Gfp (Cas9-Gfp sgRNA -EP) with a mutation frequency of 14.4% (Fig. 3E ). This is likely due to the multiple copies of GFP transgenes inserted into the genome(54) as well as an underestimation caused by T7E1 assay (53) . These results indicate that efficient genome targeting can be achieved by treatment with CriPs in primary pre-adipocytes in vitro.
Deletion of Gfp in PECs isolated from GFP transgenic mice
To determine the gene deletion efficiency using CriPs in primary GFP PECs, primary PECs that stably express GFP were isolated from GFP transgenic heterozygous mice which had been injected with thioglycollate broth. The PECs were treated with CriPs loaded with Gfp sgRNA or control CriPs loaded with Control sgRNA. On day 5 post treatment, the loss of GFP signal was determined by flow cytometry. Compared to control CriPs that showed a background shift of 2.88% (Fig. 4A ), CriPs loaded with Gfp sgRNA (Cas9-Gfp sgRNA -EP) showed a decrease of the GFP signal in 40.7% of the GFP-expressing PECs (Fig. 4B) . The relationship between Cas9-sgRNA dose and response indicated a maximum GFP loss of about 35.2% ± 4.0% in the GFPexpressing PECs when the CriPs were loaded with 100 nM of the Cas9-Gfp sgRNA complexes coated with 2 µM of the EP (Fig. 4C ). T7E1 assay showed a mutation frequency of 32.8% in the Gfp genomic DNA isolated from the cells treated with CriPs targeting Gfp, compared to a background of 2.4% in the cells treated with the control CriPs (Fig. 4D ).
Deletion of Gfp by delivery of CriPs in vivo to GFP mice
To determine the ability of CriPs to systemically deliver Cas9-sgRNA RNPs in vivo to achieve gene deletion, we administrated CriPs to mice by i.p. injections. Shown in Figure 5A , GFP transgenic heterozygous mice were i.p. injected daily for 5 days with CriPs targeting Gfp (CriPsGfp sgRNA) or with control CriPs (CriPs-Control sgRNA). On day 6, mice were sacrificed and PECs were collected and plated in cell culture. On day 13, flow cytometry was performed to measure the loss of GFP signal. Deep sequencing was also performed to detect the indels in the Gfp genomic locus. Measured by flow cytometry, a loss of the GFP signal was observed in the range of 2.9%-13.9% of the PECs (average 5.70% ± 1.07%) isolated from ten GFP transgenic heterozygous mice injected with CriPs-Gfp sgRNA. This was significantly greater than the less than 1% GFP loss we observed in the CriPs-Control sgRNA treated mice (average 0.74% ± 0.05%) (Fig. 5B and 5C ).
In order to confirm the deletion of GFP was due to genome engineering of Gfp by CriPs-Gfp sgRNA as well as to study the mutation composition of the insertions and deletions in the Gfp genomic locus, we performed deep sequencing on the PCR amplicons amplified from the genomic DNA isolated from PECs. Approximately 3% of the target sequences were mutated in the CriPs-Gfp sgRNA injected samples, corroborating the data on the GFP loss measured by flow cytometry shown in Figure 5B , while only a background noise of 0.02% was observed in the CriPs-Control sgRNA injected samples. To study the composition of the mutations in the Gfp genomic locus of the CriPs-Gfp sgRNA injected samples, the DNA sequences of the GFP wild type (WT) and the mutants were aligned (Fig. 5D) . The mutants consisted of sequences with insertions and deletions of the bases as well as SNPs in the target site.
Taken together, significant gene deletion of the Gfp gene was achieved by i.p. injections of the CriPs targeting Gfp in vivo in the GFP transgenic heterozygous mice, as determined by both flow cytometry and deep sequencing. To the best of our knowledge, this is the first study demonstrating a simple non-viral genome editing system that delivers Cas9 protein loaded with sgRNA systemically in vivo to achieve significant genome engineering. This is likely an underestimate of the efficiency since GFP expressing transgenic mice are predicted to have multiple GFP transgenes inserted into their genome(54). A higher genome engineering efficiency would be expected when editing an endogenous target gene of interest that is present in two copies.
Analysis of immune response in mice injected with CriPs
To examine the possibility of an immune response and systematic inflammation induced by CriPs, we i.p. injected WT mice daily for 5 days with CriPs loaded with a non-targeting sgRNA or PBS as a control. The systemic cytokine profile was analyzed by measuring cytokine levels (IL-1β, IL-4, IL-6, IL-10, IFNγ, TNFα) in the plasma before injection, and then 24 hours and 2 weeks after the first injection. The plasma cytokine levels (IL-10 and TNFα) in mice treated with LPS for 1.5 hours were also measured to serve as a positive control for the assay (Fig. 6D ). Figure 6A , low background levels of inflammatory cytokines were observed before i.p.
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injection of CriPs and PBS in mice. Systemic injections of CriPs did not cause an acute (24 hours) or a chronic (2 weeks) up-regulation of inflammatory cytokines such as IL-1β, IL-4, IL-10, IFNγ and TNFα in the plasma (Fig. 6B and 6C ), suggesting the absence of a broad immune response upon CriPs administration under the conditions of our experiments. Interestingly, the level of IL-6 was increased in the plasma 24 hours after the first injection in mice treated with
CriPs. IL-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine (55) . It can be significantly elevated by many factors such as exercise (56) . More importantly, IL-6 returned to a low background level when it was measured 2 weeks after the first injection. In addition, the low levels of all the plasma inflammatory cytokines measured 10 days after total 5 injections (2 weeks after the first injection) indicated that CriPs can be administrated multiple times systemically in vivo without chronic toxicity (Fig. 6C) .
Deletion of Nrip1 in primary pre-adipocytes enhances "browning"
Targeting genes in adipocytes that suppress mitochondrial uncoupling and fatty acid oxidation is a potential strategy to enhance adipocyte "browning" and energy expenditure (37) . Our laboratory has used RNAi-based screens in cultured adipocytes to identify such genes that control insulin sensitivity and energy metabolism (43) . An exciting "hit" in these screens of several thousand genes was the nuclear co-repressor Nrip1 (43) , which was also discovered in independent studies in mice (45) . NRIP1 interacts with nuclear receptors to suppress their activities to regulate genes that control glucose utilization, mitochondrial function, fatty acid oxidation and secretion of beneficial factors (43) . We and others have found that the depletion of NRIP1 in adipocytes and in mice increased fatty acid oxidation, mitochondrial respiration, insulin sensitivity and glucose tolerance (43, 45, 57) . Therefore, NRIP1 presents a potential therapeutic target for type 2 diabetes and other metabolic disorders.
In order to investigate whether the Nrip1 gene can be efficiently deleted in adipocytes and whether the depletion of Nrip1 can lead to the enhanced expression of genes associated with energy expenditure, such as UCP1, we isolated primary white pre-adipocytes from WT mice and (Fig. 7A) , elicited the most marked increase in UCP1 expression (Fig. 7B) .
The expression of other thermogenic genes, inflammatory genes and neurotropic factors were also measured by RT-PCR in the white adipocytes that had been treated with Cas9-Nrip1 sgRNA 3 -EP and Cas9-Control sgRNA -EP. Thermogenic genes involved in adipocyte "browning" (Ucp1, Cidea, Pgc1α, Prdm16, Cpt1b) were increased with the treatment of CriPs loaded with Nrip1 sgRNA 3, compared to the control CriPs (Fig. 7C) . Neurotropic factors (Nrg4, Nnat, Nrn1) were also increased with the treatment of CriPs-Nrip1 sgRNA 3 (Fig. 7E) , while inflammatory genes (Il1β, Il4, Il6, Il10, Mcp1) were not changed between CriPs-Nrip1 sgRNA 3 and CriPs-Control sgRNA groups (Fig. 7D) . Overall, these results indicate that efficient Nrip1 gene deletion was achieved in white adipocytes treated with CriPs targeting Nrip1, and the deletion of the Nrip1 gene by CriPs converts the white adipocytes to a more "brown" adipocyte phenotype known to be beneficial to whole-body metabolism in mice.
Off-target effects of CriPs targeting Nrip1 in adipocytes
Primary pre-adipocytes were treated with CriPs loaded with Nrip1 sgRNA 3 that caused the highest mutation frequency in the Nrip1 genomic locus and most increased UCP1 in differentiated adipocytes, as indicated in Figure 7 . Differentiated adipocytes were collected to measure the mutation frequencies in the on-target Nrip1 genomic locus and the off-target genomic sites. All the off-target sequences contained three mismatch bases compared to the ontarget sequence and were located in the intergenic regions. Determined by T7E1 assay, no obvious off-target effects in the adipocytes treated with CriPs targeting Nrip1 were observed compared to the non-treated cells (Fig. 8) .
DISCUSSION
A key challenge to realizing the potential of CRISPR-Cas9-based therapeutics is the assurance of safe and effective delivery to target cells(6,9). The major advance of this study is the development of a novel and simple system, CriPs, to efficiently deliver CRISPR-Cas9-based reagents in vitro and in vivo. CriPs consist of three components -Cas9 protein, sgRNA targeting genes of interest and the EP peptide, which facilitates transport of large cargoes across cell membranes (Fig 1) . As a therapeutic approach, the direct delivery of Cas9 in protein form enables the swiftest gene editing as there is no need for transcription or translation of the nuclease(7). Direct delivery of Cas9 protein offers advantages over plasmid delivery and viral delivery, which can display uncontrolled integration of DNA segments into the host genome, unwanted immune responses to the plasmids and virus, and limited packaging capacity (6) . It has been shown that the Cas9 protein introduced into cells rapidly degrades within 24 hours(52), eliminating immune responses using an ex vivo therapeutic approach where implantation of engineered cells is performed days after gene deletion. Since CriPs-mediated gene editing lasts for the lifespan of a cell, for example up to 10 years for adipocytes (58) , infrequent administration of engineered cell implants would be required to maintain therapeutic efficacy.
Characterized by DLS (Table 1) The overall positive charge on the surface of the particles is predicted to facilitate the cellular uptake by interacting with the negatively charged cell membranes. The sizes and the positive charges of CriPs were further increased when Cas9-sgRNA nanocomplexes were exposed to higher EP concentrations. Interestingly, the unchanged size of CriPs when exposed to DMEM media suggests stability of the particles in culture media.
The present study demonstrates that CriPs facilitate efficient gene deletion of the proof-ofconcept gene Gfp in multiple cell types including GFP-J774A.1 cells (Fig. 2) , GFP-PECs (Fig. 4) and primary GFP-expressing pre-adipocytes (Fig. 3) . We observed GFP loss in about 50% of cells treated with CriPs targeting Gfp, detected by flow cytometry analysis ( Fig. 2A-E, 3A -D, 4A-C) and confirmed by identification of indels in the Gfp genomic locus by T7E1 assay (Fig.   2F, 3E, 4D ). We found that the EP concentration that is optimal for maximal gene deletion is highly cell type dependent (Fig. 2E, 3B, 3D ). Primary pre-adipocytes require a much higher dose of EP to achieve maximum gene deletion compared to macrophages. On the contrary, high doses of EP are toxic to macrophages but not to primary pre-adipocytes (Fig. S3) . Gene deletion efficiency also depends on the formulations of the CriPs in different buffer systems (Fig. 3A-D) , possibly due to salts that affect the activity of the Cas9 protein and the electrostatic association of the Cas9-sgRNA nanocomplex and EP. In addition, CriPs demonstrate higher gene deletion efficiency in GFP-J774A.1 cells compared to the Cas9-sgRNA delivered by commercially available Lipofectamine® RNAiMAX (Fig. 2G and 2H ).
Although many delivery systems have been used to edit genes by Cas9-sgRNA RNPs in cell culture(30,33), primary cells (15, 19) and local areas of animals such as inner ear (4,23), skin(18), tumor(28), muscle(29) and brain (34) , systemic delivery of Cas9-sgRNA complexes using a fully non-viral system has not been previously demonstrated. To determine the ability of CriPs to delete genes in vivo by systemic delivery, we performed 5 daily i.p.
injections of CriPs targeting
Gfp (CriPs-Gfp sgRNA) or control CriPs (CriPs-Control sgRNA) in GFP transgenic heterozygous mice (Fig. 5A) . These mice showed a loss of the GFP signal in 2.91%-13.90% of the PECs when injected with CriPs-Gfp sgRNA, which was significantly higher than the CriPsControl sgRNA treated group (average 0.74% ± 0.05%) (Fig. 5B and 5C ). We also confirmed that about 3% of the target sequences were mutated in the CriPs-Gfp sgRNA injected animals, and the mutants were composed of insertions and deletions of the bases as well as SNPs (Fig.   5D ). This is likely an underestimate of the targeting efficiency since GFP transgenic mice likely have multiple Gfp transgenes inserted into their genome (54) . Taken together, our work demonstrates a simple non-viral genome editing system that delivers Cas9-sgRNA RNPs systemically in vivo to achieve significant gene deletion.
Gene editing or deletion in adipose tissue to enhance adipose tissue energy expenditure and fatty acid oxidation through a "browning" process presents a potential therapeutic approach to alleviate obesity and type 2 diabetes(37,40). Brown adipocytes not only generate heat but also secrete beneficial factors that enhance glucose tolerance in mice (38, 42) . We demonstrate the utility of CriPs-mediated gene deletion of Nrip1 in white adipocytes, demonstrating an induced "browning" phenotype with remarkably enhanced expression of UCP1, known to uncouple mitochondrial respiration, activate fatty acid oxidation and improve glucose tolerance (Fig. 7) .
Using CriPs targeting Nrip1 in the white adipocytes, we observed a highest mutation frequency of 43.8% in the Nrip1 genomic locus with Nrip1 sgRNA 3 measured by T7E1 assay (Fig. 7A ).
Adipocytes treated with the CriPs-Nrip1 sgRNA 3 that were most potent in deleting the Nrip1 gene, demonstrated the most marked increase in UCP1 expression (Fig. 7B) . Other thermogenic genes (Ucp1, Cidea, Pgc1α, Prdm16, Cpt1b) and neurotropic factors (Nrg4, Nnat, Nrn1) were also increased ( Fig. 7C and 7E ). In addition, off-target effects in adipocytes treated with CriPsNrip1 sgRNA 3 were not detected by T7E1 assay (Fig. 8) . Thus the CriPs loaded with sgRNA targeting Nrip1 provide significant potential for therapeutic development to alleviate metabolic disease.
EXPERIMENTAL PROCEDURES
Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified and were used as received. Cas9 protein was purchased from PNA BIO, INC. 
Preparation of the CriPs
Purified bacterial Cas9 protein is processed to remove endotoxin and other contaminants and is used for loading of sgRNA. The powder of Cas9 protein was resuspended in water with 20% glycerol. Cas9 protein and sgRNA were mixed in NEBuffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.9) purchased from New England Biolabs Inc. or PBS at 37 °C for 10 minutes to form nano-size complexes. The loaded Cas9-sgRNA nanocomplexes are then complexed with EP in PBS at room temperature for 15 minutes to form the final CriPs.
Characterization of the CriPs
The size of CriPs was determined by DLS (laser wavelength 633 nm) using a Malvern Zetasizer Nano-ZS particle size analyzer (Malvern Instruments, Worcestershire, UK). Solvents and buffers were filtered through 0.22 μm filters before sample preparation. EP (1mM), Cas9 (1 µM), Cas9-sgRNA (1 µM) and CriPs (1 µM) with different ratios of EP were measured for sizes upon the absence or presence of DMEM (GE Healthcare Life Sciences, Pittsburgh, PA). Zeta potentials of CriPs were also determined with a Malvern Zetasizer Nano-ZS using a Universal 'Dip' Cell Kit. 
Animals
All mice were purchased from Jackson Laboratory. WT mice (C57BL/6J) and GFP transgenic heterozygous mice (C57BL/6-Tg(UBC-GFP)30Scha/J) were used for the experiments. Mice were housed on a 12-h light/dark schedule and had free access to water and food. All procedures involving animals were approved by the Institutional Animal Care and Use Committee at the University of Massachusetts Medical School.
Isolation of primary PECs from GFP transgenic mice
Ten-week-old GFP transgenic heterozygous mice were i.p. injected with 4% thioglycollate broth (Sigma-Aldrich, St. Louis, MO). Five days following injection, the mice were sacrificed and the peritoneal cavity was washed with 5 mL of ice-cold PBS to isolate PECs. Peritoneal fluid was filtered through a 70 μm pore nylon mesh and centrifuged at 1200 rpm for 10 minutes. The pellet was first treated with red blood cell (RBC) lysis buffer (8.3 g of NH 4 Cl, 1.0 g of KHCO 3 and 0.037 g of EDTA dissolved in 1 L of water) and resuspended in DMEM supplemented with 10% (v/v) FBS, 100 μg/mL streptomycin and 100 units/mL penicillin.
In vitro CriPs treatment of primary GFP PECs
Primary GFP PECs isolated from GFP transgenic mice were plated in 12 well plates with 5x10 Rosiglitazone). After 48 hours, the media was changed to only include 1 μM Rosiglitazone and 5μg/mL insulin. After another 48 hours, the media was changed to include 5 μg/mL insulin only.
On day 5 post differentiation, the cells are considered fully differentiated.
Treatment of mouse primary white pre-adipocytes with CriPs
Gfp target gene. Primary GFP white pre-adipocytes were isolated from GFP transgenic 
Off-target effects of CriPs targeting Nrip1
Primary white pre-adipocytes were treated with CriPs (Cas9-sgRNA: 100 nM. EP: 25 µM) loaded with Nrip1 sgRNA 3. Pre-adipocytes were then differentiated to mature white adipocytes.
On day 8 post differentiation, cells were collected to measure indels in the Nrip1 genomic locus or at the off-target sites by T7E1 assay. Sequences targeting the top off-target candidate sites were determined by the CHOPCHOP program (60, 61) . Expected DNA bands cleaved by T7E1:
On-target: Uncut: 420bp, Cut: 270bp+150bp; Off-target 1: Uncut: 386bp, Cut: 283bp+103bp;
Off-target 2: Uncut: 387bp, Cut: 229bp+158bp; Off-target 3: Uncut: 352bp, Cut: 182bp+170bp.
Cytotoxicity assay post CriPs treatment in vitro
The cytotoxicity of Cas9-sgRNA coated with different EP concentrations in different cell types 
Nrip1
On-Target GGAGTCGAAGAACATCTGCATGG Off-Target 1 GGACTATAAGAACATCTGCATGG Off-Target 2 GGAGATGAAGAACATGTGCATGG Off-Target 3 GGAGAAGAAGAACCTCTGCATGG Figure 8 
